Triple Negative Breast Cancer

P1/2, N=429, Active, not recruiting, Genmab | Trial completion date: Feb 2026 --> Aug 2026

P1/2, N=60, Recruiting, Beijing Biotech

P1/2, N=19, Completed, Tasly Pharmaceutical Group Co., Ltd | Recruiting --> Completed | N=132 --> 19 | Trial completion date: Dec 2027 --> Dec 2025 | Trial primary completion date: Dec 2026 --> Jun 2025

P1/2, N=117, Active, not recruiting, Cantargia AB | Trial primary completion date: Jun 2025 --> Apr 2026

No significant association was found between TROP2 expression and other histological parameters.ConclusionLoss of ≥50% nuclear 5-hmC is a sensitive and specific marker for distinguishing mesothelioma from RMH. High TROP2 expression in tumors with high mitotic figures and higher nuclear and tumor grade suggests these patients may benefit from sacituzumab govitecan therapy.

This review synthesizes current knowledge on the unique tumor biology of breast cancer in young women, highlighting the need for precision oncology approaches that account for age-related tumor behavior. Enhanced characterization of this population may ultimately improve survival outcomes and quality of life for young women affected by breast cancer.

Targeting the ISR with small-molecule inhibitors (PERK or GCN2 inhibitors, ISRIB) or repurposed agents (metformin) demonstrates compelling preclinical efficacy in reversing immunosuppression and synergizing with immune checkpoint inhibitors. Biomarker-driven strategies, including ISR gene signatures and p-eIF2α immunohistochemistry, offer promising avenues for patient stratification. Thus, pharmacological targeting of the ISR represents a strategically viable approach to reprogram the immunosuppressive TME and overcome immunotherapy resistance in breast cancer, warranting urgent clinical investigation.

Dato-DXd demonstrated significantly improved PFS and OS versus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option. Safety was consistent with the known profile for Dato-DXd.

Taken together, these results nominate C3 as a mannose-functionalized Pt(II) candidate that exploits GLUT1 overexpression to concentrate drug in cancer cells while promoting apoptosis and restraining EMT. This functionalized based platinum approach provides a practical path toward targeted therapy for difficult breast cancer subtypes, particularly triple-negative disease.

Tumor sequencing of 42 high-priority variants identified 11 (26.2%) with wild-type allele loss and high homologous recombination deficiency. Functional CRISPR/Cas9 knock-in assays in MCF10A cells confirmed that two deep intronic variants created aberrant splice sites, disrupted splicing and impacted transcript expression.

Evaluated on a retrospective multi-center cohort of 950 breast cancer patients, our method achieved ROC-AUCs of 0.845 (95% CI: 0.801-0.886) on the internal set and 0.815 (95% CI: 0.755-0.873) on the external set, outperforming state-of-the-art benchmarks. Subgroup analysis confirmed robust performance across molecular subtypes (Luminal, HER2+, TNBC), and disease-free survival stratification affirmed its prognostic relevance, highlighting its potential to guide personalized treatment planning.